Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirabrutinib in PCNSL
NCT04947319Phase 2Active, not recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- Dec 2021
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tirabrutinib in primary central nervous system lymphoma (PCNSL) (3 arms), sponsored by Ono Pharmaceutical. Primary endpoints: Overall Response Rate at 1 year, Tirabrutinib dose estimate at 1 month and 2 more. Started Dec 2021; status: active, not recruiting.
02
Drugs
tirabrutinib
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT04947319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04947319.